Gita Ramjee Prize Awarded by the International AIDS Society and The Aurum Institute at the HIV Research for Prevention Conference.
The United States helped bring the world into the Paris climate accord, the groundbreaking global agreement reached in 2015 to reduce greenhouse gas emissions in an effort to slow climate change. Under Donald Trump, the U.S. became the only country to withdraw. Now, the U.S. is coming back.
Rising infections and new, highly contagious strains of the coronavirus are pressuring governments to accelerate vaccinations
By Dasl Yoon in Seoul, Rhiannon Hoyle in Sydney and Felicia Schwartz in Tel Aviv, The Wall Street Journal
Long-term temperature increases are associated with decreases in the diversity of children’s diets, according to a study of 100,000 children
Daisy Dunne, Climate Correspondent. The Independent
Rising temperatures are likely linked to poorer diets for children across the world, a new study suggests.
Public health experts are racing to prepare communities for the vaccine, but they face notable hurdles.
by Lilly Fowler, Crosscut
Rosalinda Martinez, a 47-year-old immigrant from Mexico who lives in Tukwila, doesn’t plan to receive the COVID-19 vaccine, even though she’s at higher risk of dying from the virus because she’s overweight and diabetic.
For nearly three decades, Grace John-Stewart, a professor of global health and epidemiology at the University of Washington School of Public Health, has devoted her career to improving HIV prevention and treatment.
Even partial protection of one dose could be enough to slow the spread of the virus, the UW Medicine researchers argue in a paper.
MEDIA CONTACT: Susan Gregg - 206.616.6730, sghanson@uw.edu
Giving one dose of the COVID-19 vaccines currently approved in the United States could curtail the spread of the SARS-CoV-19 in the community more quickly than the recommended two doses, say two vaccine experts at the University of Washington School of Medicine.
By Helen Taylor, Bobby Righi and Jonis Davis, Special to The Seattle Times
Volunteer enrollment begins for Phase III clinical trial that will determine the efficacy of Novavax vaccine candidate.
UW Medicine investigators are starting volunteer enrollment for an investigational COVID-19 vaccine clinical trial. The Phase III study will examine whether the Novavax vaccine candidate can protect against SARS-CoV-2, the coronavirus responsible for COVID-19.
As states wrestle with whether to prioritize essential workers or the elderly, Tennessee is setting aside shots for especially vulnerable areas.
By Isaac Stanley-Becker and Lena H. SunDec. 18, 2020 at 10:00 a.m. PST